What is NAGE's market cap?

$199.40M, based on the Nov 4 close of $2.52.

What is NAGE's P/E ratio?

12.5× trailing-twelve-month earnings of $15.99M.

Does Niagen Bioscience pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NAGE is sold short?

4.2M shares, 8.0% of float, as of Oct 15, 2026.

What sector is NAGE in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · NAGEHealthcarePharmaceuticals

Niagen Bioscience, Inc. Common Stock (NAGE)

$2.52+6.78%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$2.40▼ 66.80% in range

Nov 3, 2025Low $2.33 · High $7.23Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Niagen Bioscience closed at $2.52 on Nov 4, up 6.78%, 65.1% below its 52-week closing high. Volume of 675.3K shares was 1.38× its 20-day average (above normal).

Split-adjusted performance: -6.3% over one month, -49.3% over six months, -65.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $29.79M, down 4.3% from a year earlier, with a net margin of 3.2%.

Short interest was 4.2M shares at the Oct 15 settlement, up 7.8% from the prior report (8.0% of float, 6.2 days to cover).

Market cap$199.4M79.1M shares

Revenue · quarter$29.8M−4.3% YoY

Diluted EPS$0.01−75.0% YoY

P/E · TTM12.5×P/S 1.5×

Net margin3.2%Gross 64.8%

Dividend yieldNone

52-week range2.33 – 7.23−65.1% from high

Volume675.3K1.38× 20-day avg

Volatility · 60d39.7%Annualised

Short % of float8.0%6.2 days to cover

Net cash$66.7MCash $66.7M

Next earnings—Not scheduled

Split-adjusted performance

1W −0.8%1M −6.3%3M −17.1%6M −49.3%YTD −60.4%1Y −65.1%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum26

Revenue growth37

Net margin72

Value (low P/E)64

Size48

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short4.2M+7.8% vs prior

Days to cover6.2Settled Oct 15

% of float8.0%

Short vol. 10d43.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NAGENiagen Bioscience	$2.52	+6.78%	−49.3%	−4.3%	3.2%	12.5	$199.4M
TRDAEntrada Therapeutics	$5.06	+7.20%	−68.4%	−53.9%	−4762.0%	—	$197.0M	Compare
UPBUpstream Bio	$3.70	+9.14%	−59.7%	−17.5%	−5136.1%	—	$202.7M	Compare
RNACCartesian Therapeutics	$6.82	+6.40%	−18.2%	−100.0%	—	—	$206.3M	Compare
AKBAAkebia Therapeutics	$0.6947	−4.28%	−53.1%	−21.4%	−18.1%	—	$192.5M	Compare
ALXOALX Oncology Holdings	$1.36	+5.43%	−34.9%	—	—	—	$188.1M	Compare
KROSKeros Therapeutics	$10.83	0.00%	−8.1%	−100.0%	—	—	$214.7M	Compare
BBOTBridgeBio Oncology Therapeutics	$2.30	−0.86%	−72.4%	—	—	—	$184.4M	Compare
EVMNEvommune	$6.04	+1.68%	−74.7%	—	—	—	$219.2M	Compare

News about Niagen Bioscience

All news →

Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research · 2d ago▼ Negative Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineZacks Investment Research · Oct 28, 2026▼ Negative Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)Benzinga · Mar 5, 2026▲ Positive

Quick answers

What does Niagen Bioscience do?: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
What is NAGE's market cap?: $199.40M, based on the Nov 4 close of $2.52.
What is NAGE's P/E ratio?: 12.5× trailing-twelve-month earnings of $15.99M.
Does Niagen Bioscience pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NAGE is sold short?: 4.2M shares, 8.0% of float, as of Oct 15, 2026.
What sector is NAGE in?: Healthcare, in the Pharmaceuticals industry.

About Niagen Bioscience

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

HQ: Los Angeles, CA117 employeesListed Jun 24, 2008niagenbioscience.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology